effect
hydroxypropyl
methylcellulos
hpmc
methylcellulos
methocel
hg
dissolut
behavior
two
cocryst
deriv
nitazoxanid
ntz
viz
nitazoxanideglutar
acid
ntzglu
nitazoxanidesuccin
acid
ntzsuc
explor
powder
dissolut
experi
nonsink
condit
show
similar
dissolut
profil
cocryst
pure
ntz
howev
predissolv
cellulos
polym
phosphat
dissolut
medium
ph
modifi
dissolut
profil
ntz
start
cocryst
achiev
transient
drug
supersatur
subsequ
dissolut
studi
sink
condit
polymerbas
pharmaceut
powder
formul
ntzsuc
cocryst
gave
signific
improv
appar
solubl
ntz
compar
analog
formul
pure
ntz
physic
mixtur
ntz
suc
scan
electron
microscopi
powder
xray
diffract
analysi
sampl
recov
powder
dissolut
studi
show
cocryst
undergo
fast
dissolut
drug
supersatur
precipit
absenc
presenc
polym
suggest
solubil
enhanc
due
polymerinduc
delay
nucleat
crystal
growth
less
solubl
ntz
form
studi
demonstr
incorpor
appropri
excipi
adequ
concentr
key
factor
induc
maintain
solubil
poorli
solubl
drug
start
cocrystal
solid
form
way
cocryst
suitabl
develop
solid
dosag
form
improv
bioavail
efficaci
treatment
import
parasit
viral
diseas
among
other
nitazoxanid
ntz
benzamid
synthet
nitrothiazol
deriv
scheme
broad
spectrum
applic
antiparasit
antibacteri
antivir
agent
effect
protozo
infect
helminth
gram
neg
gram
posit
bacteria
divers
virus
respiratori
virus
rotaviru
noroviru
coronaviru
hepat
b
c
yellow
fever
japanes
enceph
human
immunodefici
virus
moreov
ntz
shown
anticanc
activ
suppress
product
interleukin
il
promis
compound
treatment
neuropath
pain
ebola
viru
diseas
cocryst
constitut
solid
singlephas
crystallin
materi
compos
two
molecular
andor
ionic
compound
stoichiometr
ratio
neither
solvat
simpl
salt
least
one
compon
activ
pharmaceut
ingredi
api
coform
pharmaceut
accept
substanc
recogn
pharmaceut
cocryst
pharmaceut
cocryst
offer
multipl
benefit
physicochem
biopharmaceut
properti
api
increas
solubl
dissolut
rate
improv
mechan
properti
stabil
particularli
cocryst
exhibit
higher
similar
lower
solubl
compar
parent
api
depend
natur
coform
solut
condit
solubl
advantag
cocryst
parent
drug
higher
order
magnitud
howev
also
repres
risk
due
precipit
less
solubl
form
drug
supersatur
concentr
reach
dissolut
process
due
former
behavior
cocryst
potenti
candid
develop
supersatur
drug
deliveri
system
strategi
control
cocryst
dissolut
drug
supersatur
precipit
use
supersatur
formul
incorpor
addit
excipi
cyclodextrin
surfact
polym
system
supersatur
state
must
maintain
reason
time
period
order
promot
adequ
absorpt
increas
bioavail
line
sever
recent
report
effect
polym
surfact
increas
solubl
dissolut
rate
poorli
solubl
drug
start
cocrystallin
solid
phase
repres
api
nutraceut
compound
studi
approach
celecoxib
danazol
indomethacin
carbamazepin
flufenam
acid
cilostazol
resveratrol
dihydromyricetin
tadalafil
exemestan
posaconazol
dissolut
method
nonsink
condit
commonli
use
evalu
abil
poorli
solubl
api
gener
maintain
supersatur
state
solut
addit
pharmaceut
powder
dissolut
experi
good
altern
intrins
dissolut
test
cocryst
undergo
rapid
transform
less
solubl
phase
drug
recent
found
biopharmaceut
character
cocryst
meloxicam
indomethacin
apixaban
myricetin
recent
synthesi
character
ntz
cocryst
use
succin
glutar
paminobenzo
paminosalicyl
acid
coform
report
public
improv
intrins
dissolut
rate
document
show
ntz
cocryst
improv
solubil
ntz
physiolog
relev
media
thu
good
candid
futur
develop
novel
dosag
form
herein
two
cocryst
viz
ntzglu
ntzsuc
glu
glutar
acid
suc
succin
acid
chosen
evalu
effect
two
cellulos
polym
name
hydroxypropyl
methylcellulos
hpmc
methylcellulos
methocel
hg
scheme
dissolut
perform
api
comparison
pure
ntz
commerci
avail
ntz
medicin
respect
physic
mixtur
ntz
coform
studi
includ
api
wide
use
treatment
concern
tropic
neglect
diseas
even
though
scarc
studi
purpos
work
studi
behavior
ntz
cocryst
solut
condit
sustain
supersatur
level
sinc
condit
appar
must
studi
casebycas
given
therapeut
relev
approach
formul
nitazoxanid
cocryst
benefit
improv
efficaci
consid
low
solubl
impact
bioavail
importantli
nitazoxanid
propos
potenti
agent
public
health
control
nitazoxanid
kindli
donat
laboratori
senosiain
sa
de
cv
cdmx
glutar
acid
succin
acid
hydroxypropyl
methylcellulos
hpmc
mw
kda
product
methoxyl
content
hydroxypropoxyl
content
viscos
cp
h
c
methylcellulos
methocel
hg
methocel
mc
hydroxypropyl
cellulos
hpc
hpc
polyvinylpyrrolidon
kollidon
polyethylen
glycol
kollisolv
poli
ethylen
glycol
blockpoli
propylen
glycol
blockpoli
ethylen
glycol
kolliphor
p
purchas
sigmaaldrich
st
loui
mo
usa
reagent
use
laboratori
organ
solvent
use
purchas
j
baker
chemic
co
phillipsburg
nj
usa
solvent
chemic
compound
use
receiv
without
purif
ntzglu
ntzsuc
cocryst
ntz
coform
stoichiometr
ratio
respect
synthet
liquidassist
grind
lag
techniqu
previous
report
sampl
g
ground
retsch
mixer
haan
germani
h
hz
aceton
format
cocrystallin
solid
phase
establish
comparison
powder
xray
diffract
pxrd
pattern
experiment
simul
pattern
obtain
report
xray
crystal
structur
refcod
breeinm
brenviex
total
eight
candid
polym
evalu
test
abil
maintain
ntz
solubil
methocel
mc
methocel
hg
hpmc
hpc
hpc
kollisolv
kolliphor
p
kollidon
see
tabl
polym
detail
test
perform
modifi
solvent
shift
method
propos
child
et
al
see
figur
aqueou
solut
prepar
contain
wv
predissolv
polym
ph
phosphat
buffer
solut
pb
pharmaceut
also
one
contain
buffer
solut
volum
ml
medium
place
spectrophotomet
quartz
cell
follow
stepwis
addit
total
aliquot
ntz
stock
solut
dmso
mgml
min
interv
time
abil
polymer
compound
maintain
api
dissolv
determin
analysi
presenc
absenc
precipit
ntz
solut
monitor
uvvi
spectrophotometri
measur
nm
powder
dissolut
experi
nonsink
condit
mg
pure
ntz
equival
ntz
cocryst
ad
ml
ph
buffer
dissolut
medium
ntz
sampl
pass
siev
mesh
dissolut
experi
carri
c
magnet
stir
rpm
person
reaction
station
jkem
scientif
inc
st
loui
mo
usa
sampl
ml
withdrawn
subsequ
filter
whatman
minut
first
min
everi
two
minut
min
final
min
total
sampl
dilut
ml
correspond
dissolut
medium
analyz
uvvi
spectrophotometri
nm
determin
amount
ntz
dissolv
dissolut
test
solut
contain
predissolv
hpmc
methocel
hg
polym
wv
ph
pb
employ
compar
result
obtain
polymerfre
solut
pb
alon
experi
carri
triplic
dissolut
experi
solid
residu
collect
dri
room
temperatur
analysi
powder
xray
diffract
pxrd
powder
formul
ntz
consist
physic
mixtur
compon
list
tabl
formul
three
differ
concentr
ww
methocel
hg
prepar
consid
mg
nitazoxanid
powder
mix
entri
comparison
correspond
control
experi
absenc
methocel
hg
also
obtain
entri
ntz
sampl
pass
siev
mesh
dissolut
experi
employ
usp
apparatu
powder
formul
shown
tabl
ad
volum
ml
ph
pb
solut
rotat
speed
rpm
c
sampl
ml
taken
min
equal
volum
fresh
medium
ad
maintain
dissolut
medium
volum
constant
ntz
concentr
quantifi
uvvi
spectrophotometri
nm
figur
dissolut
profil
repres
averag
three
experi
dissolut
experi
solid
residu
collect
dri
room
temperatur
analysi
pxrd
scan
electron
microscopi
sem
final
test
compar
powder
formul
methocel
hg
pharmaceut
ww
contain
mg
ntz
ntzsuc
cocryst
commerci
avail
formul
mg
tablet
perform
refer
tablet
ntz
daxon
mg
ntz
ground
agat
mortar
pass
siev
mesh
dissolut
profil
present
mg
ntz
dissolv
vs
time
mg
ntz
dissolv
calcul
c
n
concentr
drug
sampl
n
v
n
volum
dissolut
media
time
take
sampl
n
c
concentr
drug
sampl
n
v
volum
aliquot
due
sampl
solid
phase
result
ntz
cocryst
synthesi
sampl
recov
powder
dissolut
experi
examin
pxrd
analysi
use
bruker
diffractomet
bruker
bremen
germani
equip
lynxey
detector
monochrom
germanium
equip
oper
kv
data
collect
room
temperatur
rang
powder
diffract
pattern
compar
simul
pattern
singl
crystal
xray
diffract
scxrd
data
solid
residu
obtain
dissolut
test
sink
condit
analyz
sem
purpos
sampl
coat
gold
layer
sem
micrograph
captur
vega
tescan
scan
electron
microscop
tescan
orsay
hold
kohoutovic
czech
republ
kv
differ
dissolut
profil
analyz
twoway
varianc
analysi
anova
area
curv
auc
use
origin
pro
softwar
packag
originlab
co
northampton
usa
subsequ
multipl
post
hoc
test
tukey
perform
signific
level
use
statgraph
softwar
statgraph
technolog
inc
plain
va
usa
ntz
combin
glu
suc
stoichiometr
ratio
respect
use
liquidassist
grind
method
aceton
solvent
previous
report
ntzsuc
ntzglu
cocryst
prepar
scale
g
case
homogen
singl
phase
obtain
experiment
pxrd
pattern
agre
pattern
simul
crystal
structur
determin
singlecryst
xray
diffract
analysi
see
figur
batch
ten
individu
character
sampl
final
mix
use
subsequ
experi
figur
show
effect
polym
commonli
employ
pharmaceut
drug
formul
inhibit
delay
precipit
ntz
absenc
polym
addit
aliquot
ntz
stock
solut
mgml
ml
phosphat
buffer
solut
pb
ph
caus
precipit
ntz
concentr
mgml
presenc
wv
predissolv
cellulos
polym
ie
methocel
mc
methocel
hg
hmpc
hpc
hpc
well
polyvinylpyrrolidon
kollidon
precipit
ntz
inhibit
reach
concentr
least
mgml
meanwhil
polyethylen
glycol
kollisolv
poloxam
kolliphor
p
maintain
drug
dissolv
concentr
mgml
base
result
hpmc
methocel
hg
select
subsequ
powder
dissolut
experi
ntz
cocryst
phase
glu
suc
nonsink
condit
pharmaceut
x
result
hpmc
methocel
hg
select
subsequ
powder
dissolut
experi
ntz
cocryst
phase
glu
suc
nonsink
condit
powder
dissolut
profil
pure
ntz
ntzgluntzsuc
cocryst
measur
ph
phosphat
buffer
solut
absenc
presenc
predissolv
polym
wv
mgml
correspond
graph
shown
figur
absenc
polym
statist
signific
differ
p
profil
ntz
obtain
cocryst
figur
maintain
averag
satur
ntz
concentr
mgml
contrari
presenc
predissolv
hpmc
methocel
hg
ntz
dissolut
profil
pure
form
cocryst
significantli
differ
p
figur
c
thu
start
cocryst
predissolv
hpmc
methocel
hg
enabl
gener
transient
drug
concentr
approxim
mgml
time
ntz
solubl
follow
springparachut
profil
postul
guzman
et
al
supersatur
state
sustain
approxim
min
cocryst
decay
ntz
concentr
attribut
precipit
pure
ntz
indic
pxrd
analys
solid
residu
recov
dissolut
experi
ntzglu
ntzsuc
show
characterist
diffract
peak
pure
ntz
figur
overal
analysi
show
inde
ntzglu
ntzsuc
superior
dissolut
properti
compar
parent
drug
suggest
dissolut
kinet
cocrystallin
phase
extrem
rapid
supersatur
solut
precipit
short
time
period
min
agreement
previou
studi
solutionphas
stabil
ntzglu
ntzsuc
pb
ph
howev
presenc
predissolv
hpmc
methocel
hg
precipit
pure
ntz
delay
time
interv
long
enough
envis
potenti
improv
bioavail
min
see
discuss
section
powder
dissolut
profil
pure
ntz
ntzgluntzsuc
cocryst
measur
ph
phosphat
buffer
solut
absenc
presenc
predissolv
polym
wv
mgml
correspond
graph
shown
figur
absenc
polym
statist
signific
differ
p
profil
ntz
obtain
cocryst
figur
maintain
averag
satur
ntz
concentr
mgml
contrari
presenc
predissolv
hpmc
methocel
hg
ntz
dissolut
profil
pure
form
cocryst
significantli
differ
p
figur
c
thu
start
cocryst
predissolv
hpmc
methocel
hg
enabl
gener
transient
drug
concentr
approxim
mgml
time
ntz
solubl
follow
springparachut
profil
postul
guzman
et
al
supersatur
state
sustain
approxim
min
cocryst
decay
ntz
concentr
attribut
precipit
pure
ntz
indic
pxrd
analys
solid
residu
recov
dissolut
experi
ntzglu
ntzsuc
show
characterist
diffract
peak
pure
ntz
figur
overal
analysi
show
inde
ntzglu
ntzsuc
superior
dissolut
properti
compar
parent
drug
suggest
dissolut
kinet
cocrystallin
phase
extrem
rapid
supersatur
solut
precipit
short
time
period
min
agreement
previou
studi
solutionphas
stabil
ntzglu
ntzsuc
pb
ph
howev
presenc
predissolv
hpmc
methocel
hg
precipit
pure
ntz
delay
time
interv
long
enough
envis
potenti
improv
bioavail
min
see
discuss
section
abovedescrib
powder
dissolut
experi
nonsink
condit
show
best
improv
ntz
dissolut
profil
achiev
ntzsuc
cocryst
presenc
methocel
hg
evalu
polym
includ
solid
formul
effect
dissolut
kinet
cocryst
four
pharmaceut
powder
formul
examin
cocrystalpolym
ratio
ww
dissolut
perform
formul
solid
sampl
analyz
mean
powder
dissolut
test
use
usp
basket
apparatu
similar
strategi
employ
evalu
formul
cocryst
carbamazepin
dissolut
profil
ph
pb
ntz
pure
form
abovedescrib
powder
dissolut
experi
nonsink
condit
show
best
improv
ntz
dissolut
profil
achiev
ntzsuc
cocryst
presenc
methocel
hg
evalu
polym
includ
solid
formul
effect
dissolut
kinet
cocryst
four
pharmaceut
powder
formul
examin
cocrystalpolym
ratio
ww
dissolut
perform
formul
solid
sampl
analyz
mean
powder
dissolut
test
use
usp
basket
apparatu
similar
strategi
employ
evalu
formul
cocryst
carbamazepin
dissolut
profil
ph
pb
ntz
pure
form
abovedescrib
powder
dissolut
experi
nonsink
condit
show
best
improv
ntz
dissolut
profil
achiev
ntzsuc
cocryst
presenc
methocel
hg
evalu
polym
includ
solid
formul
effect
dissolut
kinet
cocryst
four
pharmaceut
powder
formul
examin
cocrystalpolym
ratio
ww
dissolut
perform
formul
solid
sampl
analyz
mean
powder
dissolut
test
use
usp
basket
apparatu
similar
strategi
employ
evalu
formul
cocryst
carbamazepin
dissolut
profil
ph
pb
ntz
pure
form
stoichiometr
physic
mixtur
ntz
suc
ntzsuc
cocryst
formul
increas
amount
methocel
hg
given
figur
pharmaceut
x
stoichiometr
physic
mixtur
ntz
suc
ntzsuc
cocryst
formul
increas
amount
methocel
hg
given
figur
figur
illustr
dissolut
profil
measur
time
interv
h
unformul
ww
methocel
hg
solid
phase
pure
ntz
physic
mixtur
suc
ntzsuc
cocryst
drug
dissolut
profil
similar
p
achiev
approxim
mg
dissolv
drug
ca
relat
mg
ntz
dose
contrast
solid
phase
formul
methocel
hg
drug
dissolv
significantli
larger
amount
either
start
pure
form
physic
mixtur
cocryst
mg
drug
dissolv
h
although
graph
associ
ntzsuc
exhibit
larger
increas
statist
differ
p
dissoci
rate
signific
due
rel
larg
standard
deviat
figur
howev
larger
amount
methocel
hg
polym
ntzsuc
cocryst
gave
significantli
improv
dissolut
profil
p
compar
analog
formul
pure
ntz
physic
mixtur
achiev
h
amount
mg
ntz
dissolv
figur
furthermor
formul
cocryst
methocel
hg
amount
ntz
dissolv
min
alreadi
approxim
mg
figur
significantli
larger
final
amount
achiev
correspond
unformul
solid
phase
figur
cocryst
solubil
quantifi
auc
area
curv
thu
constitut
paramet
indic
influenc
cocryst
api
perform
auc
directli
invers
proport
dissolut
precipit
rate
respect
figur
show
unformul
ntzsuc
cocryst
ntzsuc
formul
ww
methocel
hg
lead
improv
dissolut
profil
compar
ntz
figur
illustr
dissolut
profil
measur
time
interv
h
unformul
ww
methocel
hg
solid
phase
pure
ntz
physic
mixtur
suc
ntzsuc
cocryst
drug
dissolut
profil
similar
p
achiev
approxim
mg
dissolv
drug
ca
relat
mg
ntz
dose
contrast
solid
phase
formul
methocel
hg
drug
dissolv
significantli
larger
amount
either
start
pure
form
physic
mixtur
cocryst
mg
drug
dissolv
h
although
graph
associ
ntzsuc
exhibit
larger
increas
statist
differ
p
dissoci
rate
signific
due
rel
larg
standard
deviat
figur
howev
larger
amount
methocel
hg
polym
ntzsuc
cocryst
gave
significantli
improv
dissolut
profil
p
compar
analog
formul
pure
ntz
physic
mixtur
achiev
h
amount
mg
ntz
dissolv
figur
furthermor
formul
cocryst
methocel
hg
amount
ntz
dissolv
min
alreadi
approxim
mg
figur
significantli
larger
final
amount
achiev
correspond
unformul
solid
phase
figur
cocryst
solubil
quantifi
auc
area
curv
thu
constitut
paramet
indic
influenc
cocryst
api
perform
auc
directli
invers
proport
dissolut
precipit
rate
respect
figur
show
unformul
ntzsuc
cocryst
ntzsuc
formul
ww
methocel
hg
lead
improv
dissolut
profil
compar
ntz
physic
mixtur
ntz
suc
p
howev
formul
ww
polym
auc
ntzsuc
cocryst
increas
factor
respect
comparison
unformul
ntz
meanwhil
ntz
physic
mixtur
suc
auc
practic
constant
polym
formul
examin
herein
select
sampl
solid
residu
recov
dissolut
test
analyz
pxrd
sem
analysi
pxrd
data
show
ntzsuc
cocryst
transform
parent
drug
formul
test
figur
also
observ
dissolut
experi
nonsink
condit
peak
suc
observ
indic
coform
complet
dissolv
agreement
good
solubl
water
mgml
select
sampl
solid
residu
recov
dissolut
test
analyz
pxrd
sem
analysi
pxrd
data
show
ntzsuc
cocryst
transform
parent
drug
formul
test
figur
also
observ
dissolut
experi
nonsink
condit
peak
suc
observ
indic
coform
complet
dissolv
agreement
good
solubl
water
mgml
c
pharmaceut
x
physic
mixtur
ntz
suc
p
howev
formul
ww
polym
auc
ntzsuc
cocryst
increas
factor
respect
comparison
unformul
ntz
meanwhil
ntz
physic
mixtur
suc
auc
practic
constant
polym
formul
examin
herein
select
sampl
solid
residu
recov
dissolut
test
analyz
pxrd
sem
analysi
pxrd
data
show
ntzsuc
cocryst
transform
parent
drug
formul
test
figur
also
observ
dissolut
experi
nonsink
condit
peak
suc
observ
indic
coform
complet
dissolv
agreement
good
solubl
water
mgml
solid
residu
dissolut
test
usp
apparatu
ntzsuc
formul
ww
methocel
hg
e
ntzsuc
formul
ww
methocel
hg
f
ntzsuc
formul
ww
methocel
hg
g
ntz
formul
ww
methocel
hg
h
physic
mixtur
ntz
suc
formul
ww
methocel
hg
figur
present
sem
imag
cocryst
phase
ntzsuc
dissolut
experi
presenc
differ
amount
methocel
hg
freshli
prepar
ntzsuc
cocryst
exhibit
characterist
homogen
cylindr
morpholog
small
particl
size
figur
comparison
pure
ntz
physic
mixtur
suc
figur
b
sem
imag
solid
residu
recov
dissolut
test
ntz
physic
mixtur
formul
methocel
hg
ww
show
slight
chang
morpholog
presenc
polym
figur
pronounc
effect
occur
ntzsuc
cocryst
morpholog
sampl
chang
significantli
increas
amount
polym
figur
morpholog
presenc
polym
figur
pronounc
effect
occur
ntzsuc
cocryst
morpholog
sampl
chang
significantli
increas
amount
polym
figur
promis
result
perform
powder
formul
ntzsuc
cocryst
methocel
hg
ww
compar
commerci
avail
formul
ntz
sinc
studi
base
pharmaceut
powder
commerci
avail
refer
tablet
ntz
daxon
mg
ntz
ground
agat
mortar
sift
siev
mesh
result
powder
dissolut
experi
use
usp
type
apparatu
follow
protocol
detail
section
shown
figur
comparison
dissolut
graph
show
statist
signific
improv
dissolut
properti
formul
ntzsuc
cocryst
comparison
commerci
ntz
medicin
p
polymercocryst
formul
methocel
hg
ww
mg
drug
dissolv
bulk
solut
h
amount
dissolv
mg
ntz
min
h
commerci
product
achiev
mg
time
period
amount
mg
ntz
min
dissolv
promis
result
perform
powder
formul
ntzsuc
cocryst
methocel
hg
ww
compar
commerci
avail
formul
ntz
sinc
studi
base
pharmaceut
powder
commerci
avail
refer
tablet
ntz
daxon
mg
ntz
ground
agat
mortar
sift
siev
mesh
result
powder
dissolut
experi
use
usp
type
apparatu
follow
protocol
detail
section
shown
figur
comparison
dissolut
graph
show
statist
signific
improv
dissolut
properti
formul
ntzsuc
cocryst
comparison
commerci
ntz
medicin
p
polymercocryst
formul
methocel
hg
ww
mg
drug
dissolv
bulk
solut
h
amount
dissolv
mg
ntz
min
auc
h
commerci
product
achiev
mg
time
period
amount
mg
ntz
min
dissolv
recent
review
zaworotko
cowork
enlist
total
eight
commerci
avail
pharmaceut
cocryst
show
cocrystallin
solid
form
current
api
adequ
fabric
medicin
variou
type
therapi
time
last
year
number
public
patent
relat
pharmaceut
cocryst
increas
nevertheless
still
sever
challeng
develop
cocryst
pharmaceut
solid
dosag
form
particularli
control
behavior
cocryst
dissolut
drug
supersatur
precipit
kinet
achiev
select
suitabl
excipi
delay
nucleat
andor
crystal
maintain
adequ
drug
supersatur
level
research
project
present
herein
two
cellulos
polym
chosen
evalu
effect
maintain
supersatur
state
achiev
dissolut
cocrystallin
solid
phase
nitazoxanid
poorli
solubl
drug
subsequ
polymercocryst
powder
formul
develop
select
adequ
candid
seri
wide
use
polym
pharmaceut
industri
delay
nucleat
andor
crystal
ntz
supersatur
condit
solventshift
approach
use
see
figur
figur
demonstr
result
polym
test
ntz
ph
pb
room
temperatur
find
noncellulos
polym
kollisolv
kolliphor
significantli
help
delay
ntz
precipit
polyvinylpyrrolidon
pvpkollidon
cellulos
polym
hpc
hpc
hpmc
methocel
mc
methocel
hg
enabl
increas
concentr
ntz
aqueou
solut
least
mgml
consid
hydrogen
bond
capac
ntz
one
hbond
donor
group
nh
four
hbond
acceptor
site
observ
scheme
cellulos
polym
hpmc
methocel
hg
contain
larg
number
oh
donor
group
complementari
format
hydrogen
bond
hydrogen
bond
acceptor
explain
good
precipit
inhibitor
properti
ntz
remain
polym
test
herein
lack
strong
hbond
donor
function
could
interact
hydrogen
bond
ntz
find
support
previou
report
literatur
eg
warren
et
al
describ
effect
cellulos
polym
crystal
inhibitor
danazol
report
show
hpmc
reduc
effici
nucleat
crystal
growth
felodipin
celecoxib
nonsink
condit
moreov
reason
figur
powder
dissolut
profil
commerci
avail
formul
ntz
medicin
formul
powder
ntzsuc
cocryst
methocel
hg
ww
ph
pb
c
n
sd
recent
review
zaworotko
cowork
enlist
total
eight
commerci
avail
pharmaceut
cocryst
show
cocrystallin
solid
form
current
api
adequ
fabric
medicin
variou
type
therapi
time
last
year
number
public
patent
relat
pharmaceut
cocryst
increas
nevertheless
still
sever
challeng
develop
cocryst
pharmaceut
solid
dosag
form
particularli
control
behavior
cocryst
dissolut
drug
supersatur
precipit
kinet
achiev
select
suitabl
excipi
delay
nucleat
andor
crystal
maintain
adequ
drug
supersatur
level
research
project
present
herein
two
cellulos
polym
chosen
evalu
effect
maintain
supersatur
state
achiev
dissolut
cocrystallin
solid
phase
nitazoxanid
poorli
solubl
drug
subsequ
polymercocryst
powder
formul
develop
select
adequ
candid
seri
wide
use
polym
pharmaceut
industri
delay
nucleat
andor
crystal
ntz
supersatur
condit
solventshift
approach
use
see
figur
figur
demonstr
result
polym
test
ntz
ph
pb
room
temperatur
find
noncellulos
polym
kollisolv
kolliphor
significantli
help
delay
ntz
precipit
polyvinylpyrrolidon
pvpkollidon
cellulos
polym
hpc
hpc
hpmc
methocel
mc
methocel
hg
enabl
increas
concentr
ntz
aqueou
solut
least
mgml
consid
hydrogen
bond
capac
ntz
one
hbond
donor
group
nh
four
hbond
acceptor
site
observ
scheme
cellulos
polym
hpmc
methocel
hg
contain
larg
number
oh
donor
group
complementari
format
hydrogen
bond
hydrogen
bond
acceptor
explain
good
precipit
inhibitor
properti
ntz
remain
polym
test
herein
lack
strong
hbond
donor
function
could
interact
hydrogen
bond
ntz
find
support
previou
report
literatur
eg
warren
et
al
describ
effect
cellulos
polym
crystal
inhibitor
danazol
report
show
hpmc
reduc
effici
nucleat
crystal
growth
felodipin
celecoxib
nonsink
condit
moreov
reason
assum
cellulos
deriv
inhibit
nucleat
also
crystal
growth
agglomer
larger
size
particl
see
sem
result
otherwis
may
form
ntz
precipit
word
precipit
delay
ntz
also
attribut
surfac
interact
ntz
particl
polym
form
drugpolym
complex
deriv
modif
ntz
solubil
properti
base
larg
solubl
differ
ntz
aliphat
dicarboxyl
acid
coform
expect
cocryst
form
ntz
glu
suc
increas
aqueou
solubl
ntz
figur
show
ntzglu
ntzsuc
cocryst
dissolut
profil
similar
ntz
ph
phosphat
buffer
solut
higher
solubil
ntz
observ
condit
inde
rapid
convers
cocryst
pure
drug
demonstr
pxrd
analysi
solid
recov
dissolut
test
short
time
period
min
figur
similar
behavior
document
cocryst
phase
literatur
exampl
exemestanemaleicacid
cocryst
increas
solubil
drug
due
rapid
phase
transform
recent
public
cocryst
reinvestig
observ
transform
parent
drug
occur
less
min
fast
state
simul
intestin
fluid
fassif
critic
role
coform
physicochem
properti
solubl
dissolut
advantag
cocryst
accept
even
though
exact
mechan
enhanc
occur
fulli
understood
ntz
cocryst
studi
coform
glu
suc
ioniz
compound
pk
valu
glu
suc
exhibit
favor
water
solubl
mgml
mgml
c
respect
fast
dissolutionsupersatur
phenomenon
induc
ntz
cocryst
experiment
condit
use
herein
ph
pb
attribut
favor
solubil
coform
rapid
cocryst
dissolut
produc
drug
supersatur
level
difficult
control
absenc
suitabl
excipi
adequ
concentr
therefor
ntz
solubil
advantag
observ
use
excipi
polym
surfact
constitut
effici
strategi
prolong
drug
supersatur
achiev
pharmaceut
cocryst
addit
cellulos
polym
dissolut
medium
powder
dissolut
studi
nonsink
condit
reveal
induc
supersatur
effect
start
ntzsuc
ntzglu
cocryst
methocel
hg
hpmc
abl
maintain
drug
supersatur
time
higher
concentr
ntz
solut
solubl
valu
period
long
enough
display
superior
dissolut
profil
figur
c
phenomenon
upheld
min
emul
springparachut
effect
studi
demonstr
vitroin
vivo
correl
formul
cocryst
case
vitro
dissolut
test
show
high
drug
concentr
achiev
cocrystallin
phase
maintain
min
bioavail
correspond
poorli
solubl
drug
enhanc
consid
experiment
data
consid
increas
ntz
dissolv
ntz
cocryst
formul
polym
may
promot
ntz
absorpt
physic
stabil
ntz
cocryst
use
powder
dissolut
experi
monitor
pxrd
analysi
reveal
rapid
cocryst
dissolut
follow
drug
precipit
still
occur
presenc
polym
solut
figur
min
contact
ph
pb
powder
analyz
pxrd
analysi
indic
complet
transform
pure
ntz
pattern
exhibit
peak
indic
presenc
coform
solid
cellulos
polym
common
hydrophil
polym
use
develop
formul
cocryst
inhibit
least
delay
phase
transform
cocryst
establish
drugpolym
interact
maintain
solubil
state
api
therefor
improv
ntz
dissolut
profil
presenc
predissolv
polym
could
explain
follow
mechan
rapid
ntz
releas
solut
start
cocryst
cellulos
polym
interact
ntz
molecul
delay
nucleat
eventu
ntz
crystal
also
interact
polym
interf
crystal
growth
agglomer
process
previou
formul
cocryst
base
polym
matrix
tablet
predissolv
polym
howev
studi
test
effect
polym
incorpor
powder
solidst
form
dissolut
profil
cocryst
order
evalu
effect
methocel
hg
dissolut
process
ntzsuc
cocryst
start
solid
polymercocryst
formul
examin
seri
pharmaceut
powderbas
formul
contain
differ
amount
methocel
hg
ww
comparison
analog
form
pure
ntz
physic
mixtur
ntz
suc
absenc
polym
solid
phase
releas
similar
amount
ntz
solut
powder
dissolut
studi
use
usp
apparatu
figur
ntzsuc
cocryst
show
solubl
advantag
comparison
pure
drug
physic
mixtur
observ
attribut
immedi
convers
cocryst
phase
ntz
releas
suc
solut
accord
dissolut
experi
nonsink
condit
formul
pure
ntz
physic
mixtur
suc
ntzsuc
cocryst
ww
methocel
hg
show
dissolut
profil
similar
among
higher
concentr
ie
ww
signific
increas
dissolut
rate
observ
figur
figur
despit
inclus
polym
ntzsuc
cocryst
transform
fast
pure
ntz
reveal
pxrd
pattern
solid
residu
recov
dissolut
test
figur
howev
sem
analysi
reveal
methylcellulos
affect
significantli
particl
size
morpholog
ntz
figur
polymerntz
interact
probabl
influenc
nucleat
process
subsequ
crystal
growthagglomer
thu
give
high
drug
concentr
dissolut
medium
prolong
time
period
although
ntzpolym
interact
expect
oper
also
formul
pure
ntz
physic
mixtur
formul
lack
advantag
initi
immedi
dissolut
increas
cocryst
compon
driven
favor
coform
solubil
final
comparison
dissolut
profil
ntzsuc
cocryst
formul
methylcellulos
ww
commerci
avail
ntz
medicin
show
pharmaceut
product
contain
cocrystal
api
promissori
way
reduct
ntz
dose
might
becom
feasibl
would
larg
advantag
administr
antiparasit
drug
requir
larg
dose
howev
awar
draw
conclus
possibl
assur
therapeut
efficaci
reduc
advers
effect
vivo
studi
requir
result
present
herein
shown
ntz
cocryst
induc
superior
dissolut
behavior
presenc
hydroxypropyl
methylcellulos
hmpc
methylcellulos
methocel
hg
comparison
pure
ntz
although
rapid
transform
less
solubl
drug
form
observ
inclus
polym
formul
ntzsuc
cocryst
amount
ww
enabl
significantli
increas
dissolut
rate
ntz
compar
pure
ntz
commerci
avail
drug
formul
compar
analysi
differ
powder
formul
show
amount
polym
formul
import
paramet
consid
cocryst
formul
develop
access
good
solubil
potenti
poorli
solubl
api
aqueou
solut
conclus
use
cocryst
combin
appropri
select
pharmaceut
excipi
drug
precipit
inhibitor
retard
crystal
growth
cellulos
polym
feasibl
approach
modifi
dissolut
environ
condit
start
cocryst
result
develop
polymercocryst
powder
formul
true
altern
enhanc
solubil
poorli
water
solubl
ntz
gener
solid
dosag
form
better
bioavail
efficaci
treatment
parasit
viral
diseas
among
other
supplementari
materi
follow
data
avail
onlin
http
tabl
gener
characterist
polym
use
figur
scheme
solventshift
methodolog
employ
select
polym
delay
nucleat
andor
api
crystal
figur
uvvi
quantif
method
specif
ntz
nm
pure
ntz
cocryst
interfer
coform
quantif
method
use
herein
concentr
level
ntz
coform
observ
interfer
ntz
quantit
coform
presenc
figur
uvvi
spectra
sampl
powder
dissolut
ntz
left
ntzsuc
cocryst
right
formul
differ
concentr
methocel
hg
ntz
spectrum
chang
presenc
polym
figur
figur
sem
imag
solid
start
materi
use
powder
dissolut
test
ntz
b
physic
mixtur
ntz
suc
solid
residu
recov
dissolut
test
solid
formul
methocel
hg
c
ntz
ww
physic
mixtur
ntz
suc
ww
e
ntz
ww
f
physic
mixtur
ntz
suc
ww
note
sem
imag
start
materi
present
higher
resolut
remain
imag
see
scale
imag
